Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   37227   clinical trials with a EudraCT protocol, of which   6125   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2015-004015-20
    Sponsor's Protocol Code Number:CDRB436G2201
    National Competent Authority:France - ANSM
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2018-01-12
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedFrance - ANSM
    A.2EudraCT number2015-004015-20
    A.3Full title of the trial
    Phase II open-label global study to evaluate the effect of dabrafenib in combination with trametinib in children and adolescent patients with BRAF V600 mutation positive relapsed or refractory High Grade Glioma (HGG) P/260/2017
    Etude de phase II internationale, en ouvert, évaluant l’effet d’un traitement par dabrafenib associé au trametinib chez des enfants et des adolescents ayant un gliome de haut grade en rechute ou réfractaire avec mutation BRAF V600
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Study of efficacy and safety of dabrafenib in combination with trametinib in pediatric patients with BRAF V600 mutation positive relapsed or refractory HGG tumors
    Etude de évaluant l’effet d’un traitement par dabrafenib associé au trametinib chez des enfants et des adolescents ayant un gliome de haut grade en rechute ou réfractaire avec mutation BRAF V600
    A.4.1Sponsor's protocol code numberCDRB436G2201
    A.7Trial is part of a Paediatric Investigation Plan Yes
    A.8EMA Decision number of Paediatric Investigation PlanP/259/2017
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorNovartis Pharma AG
    B.1.3.4CountrySwitzerland
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportNovartis Pharma AG
    B.4.2CountrySwitzerland
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationNovartis Pharma S.A.S
    B.5.2Functional name of contact pointAnaïs Giraud
    B.5.3 Address:
    B.5.3.1Street Address2&4 rue Lionel Terray
    B.5.3.2Town/ cityRueil-Malmaison
    B.5.3.3Post code92400
    B.5.3.4CountryFrance
    B.5.4Telephone number+33 1 55 47 77 19
    B.5.5Fax number+33 1 55 47 67 06
    B.5.6E-mailanais.giraud@novartis.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Tafinlar
    D.2.1.1.2Name of the Marketing Authorisation holderNovartis Europharm Limited
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.2Product code DRB436
    D.3.4Pharmaceutical form Capsule, hard
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNdabrafenib
    D.3.9.1CAS number 1195765-45-7
    D.3.9.2Current sponsor codeDRB436
    D.3.9.3Other descriptive nameDABRAFENIB
    D.3.9.4EV Substance CodeSUB45696
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number50
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Tafinlar
    D.2.1.1.2Name of the Marketing Authorisation holderNovartis Europharm Limited
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.2Product code DRB436
    D.3.4Pharmaceutical form Capsule, hard
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNdabrafenib
    D.3.9.1CAS number 1195768-06-9
    D.3.9.2Current sponsor codeDRB436
    D.3.9.3Other descriptive nameDABRAFENIB
    D.3.9.4EV Substance CodeSUB45696
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number75
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Mekinist
    D.2.1.1.2Name of the Marketing Authorisation holderNovartis Europharm Limited
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.2Product code TMT212
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNtrametinib
    D.3.9.1CAS number 1187431-43-1
    D.3.9.2Current sponsor codeTMT212
    D.3.9.3Other descriptive nameTRAMETINIB DIMETHYL SULFOXIDE
    D.3.9.4EV Substance CodeSUB45696
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number0.5
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 4
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Mekinist
    D.2.1.1.2Name of the Marketing Authorisation holderNovartis Europharm Limited
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.2Product code TMT212
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNtrametinib
    D.3.9.1CAS number 1187431-43-1
    D.3.9.2Current sponsor codeTMT212
    D.3.9.3Other descriptive nameTRAMETINIB DIMETHYL SULFOXIDE
    D.3.9.4EV Substance CodeSUB45696
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number2
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 5
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.2Product code TMT212
    D.3.4Pharmaceutical form Powder for oral solution
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNtrametinib
    D.3.9.1CAS number 1187431-43-1
    D.3.9.2Current sponsor codeTMT212
    D.3.9.3Other descriptive nameTRAMETINIB DIMETHYL SULFOXIDE
    D.3.9.4EV Substance CodeSUB45696
    D.3.10 Strength
    D.3.10.1Concentration unit mg/g milligram(s)/gram
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number0.41
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Paediatric patients with BRAF V600 mutation positive relapsed or refractory High Grade Glioma (HGG)
    Patients pédiatriques atteints de mutation BRAF V600 positif Retapé ou réfractaire gliome de haut grade (HGG)
    E.1.1.1Medical condition in easily understood language
    Children and adolescents with a form of brain tumor called high-grade glioma, which is characterised by a mutation in the BRAF V600 gene
    Les enfants et les adolescents ayant une forme de tumeur cérébrale appelée gliome de haut grade (HGG), qui se caractérise par une mutation du gène BRAF V600
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10065443
    E.1.2Term Malignant glioma
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    Evaluate the anti-tumor activity of dabrafenib in combination with trametinib, as measured by overall response rate (ORR) to the combination therapy by investigator assessment using the RANO criteria.
    Evaluation de l’activité anti-tumorale du dabrafenib associé au trametinib, mesurée par le taux de réponse globale (ORR) aux traitements, qui sera évalué par le médecin-investigateur selon les critères RANO (Response Assessment in Neuro-Oncology)
    E.2.2Secondary objectives of the trial
    1. Evaluate ORR by central independent review
    2. Evaluate duration of response (DOR) by investigator and central independent review
    3. Evaluate time to response (TTR) by investigator and central independent review
    4. Evaluate progression free survival (PFS) by investigator and central independent review
    5. Evaluate overall survival (OS)
    6. Evaluate the safety profile of dabrafenib in combination with trametinib in children and adolescents
    7. Characterize the pharmacokinetics of dabrafenib, its metabolites and trametinib in the study population
    1. Evaluation du ORR par un comité de revue indépendant centralize
    2 .Evaluation de la durée de réponse (DOR) par le médecin-investigateur et par un comité de revue indépendant centralize
    3. Evaluation du délai de réponse (TTR) par le médecin-investigateur et par un comité de revue indépendant centralize
    4. Evaluation de la Survie sans progression (PFS) par le médecin-investigateur et par un comité de revue indépendant centralize
    5. Evaluation de la Survie globale (OS)
    6. Evaluation de l’innocuité du dabrafenib associé au trametinib chez des enfants et des adolescents
    7. Description du profil pharmacocinétique (PK) du dabrafenib, de ses métabolites et du trametinib dans la population à l’étude.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    Key Inclusion criteria:
    - Male or female between ≥ 6 and <18 years of age at the time of signing the informed
    consent form
    - Relapsed, progressed, or failed to respond to frontline therapy. Frontline therapy is
    presumed to be optimal surgical approach (biopsy or resection) with radiation and/or
    chemotherapy.
    - Histologically confirmed diagnosis of High Grade Glioma (Grade III or IV glioma as
    defined by WHO histological classification system, revised 2016, see Appendix 4),
    including anaplastic pleomorphic xanthoastrocytoma (aPXA) and anaplastic
    gangliogliomas.
    - Locally determined and centrally confirmed measurable disease with minimal biperpendicular diameter that must be at least twice the imaging slice thickness to be used for efficacy assessments. (Both local and centrally confirmed results must show
    measurable disease to meet eligibility)
    - BRAF V600 mutation-positive tumor as locally determined using molecular methods in a
    CLIA-approved laboratory or equivalent, or at a Novartis designated central reference
    laboratory upon request
    - Tumor tissue (newly obtained or archival paraffin blocks/slides) must be available and
    subsequently provided to Novartis for central confirmatory testing of HGG histopathology
    and BRAF mutational status.
    - Performance score of ≥50% according to the Karnofsky/Lansky performance status scale
    - Females of child-bearing potential must be willing to practice acceptable methods of birth control. Additionally, females of childbearing potential must have a negative serum
    pregnancy test within 7 days prior to day 1
    - Must have adequate bone marrow function in the absence of growth factor support and is defined as:
     -Absolute neutrophil count (ANC) ≥1000/μL;
     -Platelets ≥75,000/μL and transfusion independent, defined as not receiving platelet
    transfusions within a 7 day period prior to meeting this enrollment criteria
     -Hemoglobin ≥8.0 g/dL (may receive red blood cell transfusions)
    - Adequate renal function defined as:
     -Calculated eGFR (Schwartz formula, http://www.medcalc /pedigfr.html), or
    radioisotope GFR ≥90 mL/min/1.73 m2; or
     -A serum creatinine within the testing lab reference range (for age/gender, if available)
    - Adequate liver function defined as:
     -Bilirubin (sum of conjugated + unconjugated) ≤ 1.5 x upper limit of normal (ULN)
    for age
     -AST and ALT ≤2.5 x ULN
    - Adequate cardiac function defined as:
     -LVEF greater than or equal to institutional LLN by ECHO (while not receiving
    medications for cardiac function)
     -Corrected QT (QTcF) interval ≤480 msecs.
    - Able to swallow capsules:
     -If less than 12 years old, must be ≥ 16kg body weight
     -If ≥ 12 years old, must be ≥ 19kg body weight
    - If receiving glucocorticoids, patient must be on a stable or weaning dose for at least 7 days prior to the first dose of study treatment.
    - Written informed consent/assent must be obtained prior to any protocol specific screening procedures being performed.
    Les patients éligibles pour participer à cette étude doivent remplir tous les critères suivants :
    -Enfants et adolescents masculins ou féminins âgés de ≥ 6 ans à < 18 ans au moment de la signature du consentement éclairé.
    -Rechute, progression, ou absence de réponse au traitement de première ligne. Le traitement de première ligne est considéré comme étant l’approche chirurgicale optimale (biopsie ou résection) avec radiothérapie et/ou chimiothérapie.
    -Confirmation histologique du GHG (grade III ou IV selon la classification histologique de l’OMS révisée en 2016), y compris le xanthoastrocytome pléomorphe anaplasique et les gangliogliomes anaplasiques.
    -Tumeur mesurable, déterminée localement et confirmée en central, avec un diamètre bi-perpendiculaire minimal qui doit être d’au moins 2 fois l’épaisseur de coupe de l’imagerie utilisée pour les évaluations d’efficacité (les résultats en local et ceux confirmés en central doivent montrer une tumeur mesurable pour satisfaire ce critère d’inclusion).
    -Tumeur positive pour la mutation BRAF V600, déterminée localement par des méthodes d’analyses moléculaires dans un laboratoire agréé CLIA (Clinical Laboratory Improvement Amendments) ou équivalent, ou sur demande, dans un laboratoire central de référence désigné par Novartis.
    -Un échantillon tumoral (bloc/lames inclus dans la paraffine, nouveaux ou archivés) doit être disponible et fourni à Novartispour une confirmation histologique centralisée du GHG et du statut mutationnel BRAF
    -Indice de performance ≥ 50 % selon l’échelle de performance Karnofsky/Lansky.
    -Les femmes en âge d’avoir des enfants doivent utiliser une méthode de contraception acceptable. De plus, un test de grossesse sérique doit avoir été réalisé et être négatif dans les 7 jours précédant le début des traitements à l’étude.
    -Avoir une fonction médullaire adéquate en absence de traitement par facteurs de croissance, comme définie ci-dessous :
    • Nombre absolu de neutrophiles ≥ 1000/μl.
    • Plaquettes ≥ 75 000/μl, indépendamment de transfusions, c’est-à-dire n’ayant pas reçu de transfusion de plaquettes dans les 7 jours précédant l’inclusion afin de remplir ce critère.
    • Hémoglobine ≥ 8,0 g/dl (transfusions de globules rouges autorisées).
    -Fonction rénale adéquate, comme définie ci-dessous :
    • Taux de filtration glomérulaire estimé (eGFR) (formule de Schwartz, http://www.medcalc.com/pedigfr.html), ou GFR radioisotope ≥ 90 ml/min/1,73 m2, ou
    • Créatinine sérique dans la norme de référence du laboratoire d’analyses (pour l’âge et le sexe, si disponible)
    -Fonction hépatique adéquate, comme définie ci-dessous :
    • Bilirubine (conjuguée plus non conjuguée) ≤ 1,5 x la limite supérieure de la normale (LSN) pour l’âge.
    • Aspartate aminotransférase (ASAT) et alanine aminotransférase (ALAT) ≤ 2,5 x LSN.
    -Fonction cardiaque adéquate, comme définie ci-dessous :
    • Fraction d’éjection du ventricule gauche supérieure ou égale à la limite inférieure de la normale selon les valeurs de références de l’hôpital, mesurée par échocardiographie (sans traitement pour la fonction cardiaque).
    • Intervalle QT corrigé d’après la formule de Fridericia (QTcF) ≤ 480 msec.
    -Etre capable d’avaler des gélules :
    • Poids ≥ 16 kg chez les enfants de moins de 12 ans
    • Poids ≥ 19 kg chez les enfants de 12 ans et plus
    -Les patients traités par glucocorticoïdes doivent être sous une dose stable ou avoir arrêté tout traitement glucocorticoïde depuis au moins 7 jours avant la première dose de traitements à l’étude.
    -Un consentement éclairé écrit ou assentiment devra être obtenu avant toute procédure de sélection spécifique à l’étude.
    E.4Principal exclusion criteria
    - Malignancy OTHER than BRAF V600 mutant HGG.
    - Previous treatment with dabrafenib or another RAF inhibitor, trametinib or another MEK
    inhibitor, or ERK inhibitor.
    - Cancer therapy (chemotherapy with delayed toxicity, immunotherapy, biologic therapy,
    vaccine therapy) or investigational drugs within 3 weeks preceding the first dose of study
    treatment.
    - Radiotherapy to CNS glioma lesions within 3 months prior to first dose of study treatment, unless there is clear evidence of radiologic progression outside of the field of radiation.
    - History of malignancy with confirmed activating RAS mutation or with BRAF fusion
    such as BRF-KIAA1549. Note: Prospective RAS testing is not required. However, if the
    results of previous RAS testing are known, they must be used in assessing eligibility.
    - Current use of a prohibited medication or herbal preparation or requires any of these
    medications during the study. See Section 6.4 for details.
    - Unresolved toxicity greater than NCI CTCAE v 4.03 grade 2 from previous anti-cancer
    therapy, including major surgery, except those that in the opinion of the investigator are
    not clinically relevant given the known safety/toxicity profile of the study treatment (e.g.,
    alopecia and/or peripheral neuropathy related to platinum or vinca alkaloid based
    chemotherapy).
    - History of allergic reactions attributed to compounds of similar chemical or biologic
    composition to dabrafenib, trametinib and their excipients.
    - Autologous or allogeneic stem cell transplant within 3 months prior to the first dose of
    study treatment
    - History or current diagnosis of cardiac disease indicating significant risk of safety for
    patients participating in the study such as uncontrolled or significant cardiac disease,
    including any of the following:
     recent myocardial infarction (within last 6 months),
     uncontrolled congestive heart failure,
     unstable angina (within last 6 months),
     clinically significant (symptomatic) or known, uncontrolled cardiac arrhythmias (e.g.,
    sustained ventricular tachycardia, and clinically significant second or third degree AV
    block without a pacemaker) except sinus arrhythmia within the past 24 weeks prior to
    the first dose of study treatment
     coronary angioplasty or stenting (within last 6 months)
     intra-cardiac defibrillators
     abnormal cardiac valve morphology (≥grade 2) documented by echocardiogram
    (patients with grade 1 abnormalities can be enrolled on study. Patients with moderate valvular thickening should NOT be enrolled)
    - Uncontrolled medical conditions (e.g., diabetes mellitus, hypertension, liver disease or
    uncontrolled infection), psychological, familial, sociological, or geographical conditions
    that do not permit compliance with the protocol; or unwillingness or inability to follow the procedures required in the protocol
    - Presence of active GI disease or other condition (e.g., small bowel or large bowel
    resection) that will interfere significantly with the absorption of drugs.
    - A history of Hepatitis B Virus, or Hepatitis C Virus infection (patients with laboratory
    evidence of cleared Hepatitis B Virus and/or Hepatitis C Virus may be enrolled).
    - Women of child-bearing potential, defined as all women physiologically capable of
    becoming pregnant (e.g. are menstruating), unless they are using highly effective methods of contraception during dosing of study treatment and for 4 months after stopping study medication. Effective contraception methods include:
     Total abstinence (when this is in line with the preferred and usual lifestyle of the
    patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation
    methods) and withdrawal are not acceptable methods of contraception
     Female sterilization (have had surgical bilateral oophorectomy with or without
    hysterectomy), total hysterectomy, or bilateral tubal ligation or tubal occlusion at least
    six weeks before taking study treatment. In case of oophorectomy alone, only when
    the reproductive status of the woman has been confirmed by follow up hormone level
    assessment is she considered not of child bearing potential.
     Male sterilization (at least 6 months prior to screening). For female patients on the
    study, the vasectomized male partner should be the sole partner for that patient.
     Placement of a non-hormonal intrauterine device (IUD) or intrauterine system (IUS)
    with a documented failure rate of less than 1% per year. Double-barrier contraception:
    condom and occlusive cap (diaphragm or cervical/vault caps) with a vaginal
    spermicidal agent (foam/gel/cream/suppository).
    -Tumeur autre que le GHG positif pour la mutation BRAF V600.
    -Traitement antérieur par dabrafenib ou un autre inhibiteur de RAF, par trametinib ou un autre inhibiteur de MEK ou par un inhibiteur de ERK.
    -Traitement anticancéreux (chimiothérapie pouvant causer une toxicité différée, immunothérapie, thérapie biologique, vaccination) ou autres médicaments expérimentaux dans les 3 semaines précédant la première dose de traitements à l’étude.
    -Radiothérapie pour le traitement des lésions du gliome au niveau du système nerveux central (SNC) dans les 3 mois précédant la première dose de traitements à l’étude sauf s’il y a une progression radiologique évidente en dehors du champ de radiation
    -Antécédents de tumeur avec mutation RAS confirmée ou avec une fusion BRAF telle que BRF-KIAA1549. Remarque : Un test prospectif pour RAS n’est pas requis. Cependant, si des résultats antérieurs pour la mutation RAS sont connus, ils doivent être utilisés pour évaluer l’éligibilité.
    -Utilisation au moment de la sélection de médicaments interdits ou de préparation à base de plantes ou nécessité de suivre l’un de ces médicaments durant l’étude.
    -Toxicité non résolue > grade 2 (selon NCI CTCAE version 4.03) causée par les traitements anticancéreux antérieurs, incluant une chirurgie majeure, exceptés ceux qui, selon le médecin-investigateur, ne sont pas cliniquement pertinents compte tenu du profil connu de tolérance et de toxicité des traitements à l’étude (par ex. : alopécie et/ou neuropathie périphérique liée à une chimiothérapie à base de platine ou de vinca-alcaloïdes).
    -Antécédents de réactions allergiques à des produits ayant une composition chimique ou biologique similaire au dabrafenib, au trametinib et à leurs excipients.
    -Greffe de cellules souches autologues ou allogéniques dans les 3 mois précédant la première dose des traitements à l’étude (Remarque : les patients présentant une réaction active du greffon contre l’hôte sont exclus quel que soit le temps écoulé).
    -Antécédents ou diagnostic récent de maladie cardiaque présentant un risque significatif pour la sécurité des patientsparticipant à l’étude, comme des cardiopathies significatives ou non contrôlées telles que :
    Infarctus du myocarde récent (dans les 6 derniers mois)
    Insuffisance cardiaque congestive non-contrôlée
    Angor instable (dans les 6 derniers mois)
    Arythmies cardiaques cliniquement significatives (symptomatiques) ou connues non-contrôlées excepté les arythmies sinusales dans les 24 heures avant la première dose de traitements à l’étude
    Angioplastie coronarienne ou implantation d’une endoprothèse cardiaque (dans les 6 mois)
    Défibrillateur intracardiaque
    Anomalie morphologique des valves cardiaques (≥ grade 2) documentée par échocardiographie (les patients avec des anomalies de grade 1 [par ex. : régurgitation/sténose légère] peuvent participer à l’étude). Les patients présentant un épaississement valvulaire modéré ne doivent PAS participer à l’étude
    -Maladies non-contrôlées, problèmes psychologiques, familiaux, sociaux ou géographiques qui ne permettent pas de se conformer au protocole; ou refus ou incapacité de suivre les procédures requises dans le protocole.
    -Maladie gastro-intestinale ou toute autre condition (par ex. : résection de l’intestin grêle ou du colon) qui pourrait interférer avec l’absorption des médicaments de manière significative.
    -Antécédents d’infection par le virus de l’hépatite B ou C (les patients ayant une preuve biologique de la disparition du virus de l’hépatite B ou C peuvent participer à l’étude).
    -Femmes en âge d’avoir des enfants, c’est-à-dire toutes les femmes physiologiquement aptes à être enceinte (ayant eu leurs règles) sauf si elles utilisent une méthode de contraception très efficace pendant toute la période de traitement et pendant 4 mois après l’arrêt des traitements à l’étude. Les méthodes de contraception efficaces incluent :
    Abstinence totale (lorsque cela est en accord avec les préférences et le style de vie de la patiente). L’abstinence périodique et le retrait ne sont pas considérés comme des méthodes de contraception
    acceptables.
    Stérilisation féminine (femmes ayant eu une ovariectomie bilatérale avec ou sans hystérectomie), hystérectomie totale, occlusion ou ligature bilatérale des trompes au moins 6 semaines avant le début des traitements à l’étude. Dans le cas d’une ovariectomie seule, le statut reproductif de la femme doit être confirmé par un suivi des concentrations hormonales.
    Stérilisation masculine (au moins 6 mois avant la phase de sélection). Pour les femmes participant à l’étude, le partenaire masculin vasectomisé doit être leur seul partenaire.
    Placement d’un dispositif ou système intra-utérin ayant un taux d’échec < 1 % par an. Double contraception : préservatif et cape occlusive (diaphragme ou cape cervicale) associé avec un spermicide vaginal (en gel, crème, mousse, film ou ovule).
    E.5 End points
    E.5.1Primary end point(s)
    ORR, proportion of patients with a best overall confirmed Complete Response (CR) or Partial Response (PR) by investigator assessment per Response Assessment in Neuro-Oncology (RANO) criteria.
    ORR, proportion de patients ayant une réponse complète confirmée globale (CR) ou une réponse partielle (PR) confirmée par l'évaluation de l'enquêteur par évaluation de la réponse en critères de neuro-oncologie (RANO).
    E.5.1.1Timepoint(s) of evaluation of this end point
    Patients will be assessed at screening (before initiation of study treatment) and every 8 weeks for the first year on treatment, and every 16 weeks thereafter for efficacy using RANO criteria.
    Les patients seront évalués lors du dépistage (avant l'initiation du traitement à l'étude) et toutes les 8 semaines pour la première année de traitement, et toutes les 16 semaines par la suite pour l'efficacité en utilisant les critères RANO.
    E.5.2Secondary end point(s)
    1. ORR by central independent review assessment per RANO criteria
    2. DOR, calculated as the time from the date of the first documented confirmed response (CR or PR) to the first documented progression or death due to any cause, as assessed separately by investigator and central independent reviewer per RANO criteria.
    3. TTR, calculated as the time from the start date of study treatment to first documented confirmed response CR or PR (which must be confirmed subsequently) as assessed separately by investigator and independent central reviewer per RANO criteria
    4. PFS, defined as time from first dose of study treatment to progression or death due to any cause, as assessed separately by central independent reviewer and investigator per RANO criteria
    5. OS, defined as the time from first dose of study treatment to death due to any cause
    6. Incidence of adverse events and serious adverse events, changes in laboratory results, vital signs, ECG and ECHO
    7. Plasma concentration-time profiles of dabrafenib, its metabolites and trametinib and PK parameters
    1. ORR par évaluation d'évaluation indépendante centrale selon les critères de RANO
    2. DOR, calculé comme le moment de la première réponse confirmée documentée (CR ou PR) à la première progression documentée ou à la mort due à une cause, évaluée séparément par l'enquêteur et l'évaluateur indépendant central selon les critères de RANO.
    3. TTR, calculé comme le temps compris entre la date de début du traitement de l'étude et la première réponse confirmée documentée CR ou PR (qui doit être confirmée ultérieurement), évaluée séparément par l'enquêteur et l'évaluateur central indépendant selon les critères RANO
    4. PFS, défini comme le temps de la première dose de traitement d'étude à la progression ou à la mort en raison de toute cause, évalué séparément par un examinateur indépendant central et un enquêteur selon les critères de RANO
    5. OS, défini comme le temps de la première dose de traitement d'étude à la mort en raison de toute cause
    6. Incidence d'événements indésirables et d'effets indésirables graves, changements de résultats de laboratoire, signes vitaux, ECG et ECHO
    7. Profils plasmatiques de concentration-temps de dabrafenib, ses métabolites et les paramètres de trametinib et de PK
    E.5.2.1Timepoint(s) of evaluation of this end point
    Patients will be assessed at screening (before initiation of study treatment) and every 8 weeks for the first year on treatment, and every 16 weeks thereafter for efficacy using RANO criteria.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial1
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned5
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA26
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Argentina
    Australia
    Brazil
    Canada
    Czech Republic
    Denmark
    Finland
    France
    Germany
    Italy
    Japan
    Netherlands
    Spain
    Sweden
    Switzerland
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years6
    E.8.9.1In the Member State concerned months7
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years6
    E.8.9.2In all countries concerned by the trial months7
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 Yes
    F.1.1Number of subjects for this age range: 40
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) Yes
    F.1.1.5.1Number of subjects for this age range: 15
    F.1.1.6Adolescents (12-17 years) Yes
    F.1.1.6.1Number of subjects for this age range: 25
    F.1.2Adults (18-64 years) No
    F.1.3Elderly (>=65 years) No
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally Yes
    F.3.3.6.1Details of subjects incapable of giving consent
    Minors
    F.3.3.7Others Yes
    F.3.3.7.1Details of other specific vulnerable populations
    Majority of patients with pediatric high-grade glioma are incurable
    F.4 Planned number of subjects to be included
    F.4.1In the member state6
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 15
    F.4.2.2In the whole clinical trial 40
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    After discontinuation of study treatment, patients will be followed for safety for at least 30 days after the last dose of study treatment except in the case of death, loss to follow-up or withdrawal of consent.Tumor evaluations during this period will continue until documented disease progression by RANO criteria, withdrawal of consent by subject to tumor status follow-up.All patients will be followed for survival once they discontinue study treatment and tumor evaluations for at least 2 years.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2017-12-29
    N.Ethics Committee Opinion of the trial application
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2018-10-17
    As of 1.2.2020, the UK is no longer an EU Member State. However, EU law still applies to the UK during the transition period
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2020 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA